Judgement Briefs

Intellectual Property Rights

Novartis A.G. v. Union of India

(2013) 6 SCC 1; AIR 2013 SC 1311

Citation
(2013) 6 SCC 1; AIR 2013 SC 1311
Court
Supreme Court of India
Date
1 April 2013
Bench
Aftab Alam and Ranjana Prakash Desai JJ.

Facts

  • Novartis filed an Indian patent application for the beta crystalline form of imatinib mesylate, a substance used in the cancer medicine marketed as Glivec.
  • An earlier patent, commonly called the Zimmermann patent, had already disclosed the compound imatinib and its pharmaceutically acceptable salts.
  • Novartis claimed that the beta crystalline form was a new and superior form because it had:
  • better flow properties;
  • greater thermodynamic stability;
  • lower hygroscopicity; and
  • approximately 30% greater bioavailability.
  • The Patent Office rejected the application, principally under Section 3(d) of the Patents Act, 1970.
  • Section 3(d) prevents patenting of a new form of a known substance unless it shows an enhancement of the known substance’s efficacy.
  • The Intellectual Property Appellate Board also refused the patent.
  • Novartis appealed to the Supreme Court, arguing that the beta crystalline form was both inventive and therapeutically more useful.

Issue

  • Whether the beta crystalline form of imatinib mesylate was a patentable invention.
  • Whether it was a “new form of a known substance” under Section 3(d).
  • What “efficacy” means when Section 3(d) is applied to a pharmaceutical product.
  • Whether better physical properties and increased bioavailability proved enhanced therapeutic efficacy.

Rule

  • A patent applicant must ordinarily establish novelty, inventive step and industrial applicability.
  • Section 3(d) imposes an additional requirement when the claim concerns a new form of a known substance.
  • Such a new form is not patentable unless it results in enhancement of the known efficacy of that substance.
  • In the case of medicines, “efficacy” primarily means therapeutic efficacy.
  • Improved properties such as:
  • stability;
  • flow;
  • storage;
  • solubility; or
  • bioavailability may be relevant only when evidence shows that they actually enhance therapeutic performance.
  • Section 3(d) does not prohibit every incremental pharmaceutical invention. It prevents patents for minor modifications that do not demonstrate meaningful enhancement of efficacy.

Application

  • The Court first examined what was already known before Novartis claimed the beta crystalline form.
  • The earlier Zimmermann patent disclosed imatinib and its salts and described their anti-tumour properties.
  • The Court treated imatinib mesylate as a known substance for applying Section 3(d).
  • Therefore, Novartis had to do more than show that the beta crystalline form was physically different.
  • Better flow and reduced hygroscopicity could make a drug easier to manufacture or store, but they did not directly show that it treated cancer more effectively.
  • Thermodynamic stability similarly concerned the physical condition of the substance rather than its therapeutic action in the human body.
  • Novartis relied strongly on the claim of approximately 30% higher bioavailability.
  • The Court accepted that bioavailability could, in an appropriate case, contribute to increased therapeutic efficacy.
  • However, improved bioavailability does not automatically prove better therapeutic effect.
  • The applicant had to provide research or clinical evidence connecting the increased bioavailability with better treatment outcomes.
  • Novartis had not produced sufficient evidence showing that the beta crystalline form:
  • produced a stronger therapeutic response;
  • required a meaningfully reduced dosage;
  • improved patient outcomes; or
  • otherwise treated the disease more effectively than the known substance.
  • The Court explained that Section 3(d) was intended to prevent evergreening, where minor changes are used to extend patent monopolies without genuine therapeutic advancement.
  • At the same time, the Court clarified that a genuinely improved form supported by evidence of enhanced efficacy could still be patented.

Conclusion

  • The Supreme Court refused the patent.
  • The beta crystalline form was treated as a new form of the known substance imatinib mesylate.
  • Novartis failed to establish enhanced therapeutic efficacy as required by Section 3(d).
  • Improved physical properties and unsupported claims of increased bioavailability were insufficient.
  • The Court did not hold that all incremental inventions are unpatentable; it required proof of a meaningful efficacy enhancement.
  • Use this case for: a new pharmaceutical form must demonstrate enhanced therapeutic efficacy, not merely better physical or manufacturing properties, to overcome Section 3(d).